Filtered By:
Procedure: Heart Transplant

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 1298 results found since Jan 2013.

Increased Pump Speed is Associated with Reduced Rates of Stroke on HeartMate II LVAD Support
Higher pump speeds have recently been associated with reduced rates of pump thrombosis in the HeartMate II LVAD population. Whether pump speed is associated with stroke has not been well established. In this analysis we use a single center cohort to determine the association with discharge speed and all-cause stroke.
Source: The Journal of Heart and Lung Transplantation - March 31, 2018 Category: Transplant Surgery Authors: J.N. Schultz, R. Cogswell, M. Prtizker, E. Missov, K. Liao, J. Misialek, R. John Source Type: research

Predictive Value of Mean Arterial Pressure Versus Systolic Blood Pressure and Visit-To-Visit Blood Pressure Variability for Stroke and Pump Thrombosis in HeartMate II Patients
Elevated blood pressure (BP) in pts on left ventricular assist device (LVAD) support is a risk factor for adverse events (AEs) such as stroke and pump thrombosis (PT). Current guidelines recommend a mean arterial pressure (MAP) ≤ 80mmHg. Above-median systolic BP (SBP) at discharge after HeartMate II (HMII) implant has been associated with an increased risk of stroke. We sought to 1) compare the predictive value of outpt MAP and SBP on AEs, 2) examine the association of visit-to-visit variability (VVV) of BP with AEs in H MII pts.
Source: The Journal of Heart and Lung Transplantation - March 31, 2018 Category: Transplant Surgery Authors: A. Pinsino, F. Castagna, J.Z. Willey, A.M. Zuver, M.A. Flannery, B. Cagliostro, J.R. Cockroft, A.R. Garan, V.K. Topkara, H. Takayama, K. Takeda, Y. Naka, R.T. Demmer, P.C. Colombo, M. Yuzefpolskaya Source Type: research

Blood Pressure Control as a Risk Factor for Stroke in LVAD Patients- Single Center Experience
The ENDURANCE trial suggested an increased stroke (CVA) risk in Heartware HVAD compared to Heartmate 2 (HM2); a risk that could be mitigated with improved blood pressure control as demonstrated in the ENDURANCE 2 supplemental study. We hypothesized that better blood pressure control reduced the stroke risk in all LVAD supported patients.
Source: The Journal of Heart and Lung Transplantation - March 31, 2018 Category: Transplant Surgery Authors: N.S. Clarke, R. Vela, J. Pruszynski, M. Drazner, L.C. Huffman, M. Peltz Source Type: research

Early stroke post –heart transplant is associated with decreased survival in children
In this study we aimed to characterize early MNEs (stroke, isolated seizures not from stroke and posterior reversible leukoencephalopathy [PRES] within 1 year after primary pediatric HTx) and evaluate their impact on 1-year post-HTx survival. We hypothesized that early an MNE after HTx is associated with decreased 1-year patient survival.
Source: The Journal of Heart and Lung Transplantation - January 8, 2018 Category: Transplant Surgery Authors: Cheryl Cammock, Swati Choudhry, Chesney M. Castleberry, Noor Al-Hammadi, Pirooz Eghtesady, Charles E. Canter, Kathleen E. Simpson Tags: Original Clinical Science Source Type: research

SynCardia responds to FDA note warning of high rates of stroke, mortality risk with TAH-t C2 Driver
SynCardia Systems this week responded to an FDA notice warning about a higher mortality risk and stroke rate with the company’s Temporary Total Artificial Heart Companion 2 Driver System noted as part of a post-approval study of the device. In its response, the Tucson, Ariz.-based company said that the FDA letter, which warned of risks associated with the next-gen C2 driver, was not a recall notice, and that hospitals should continue to use the C2 driver without restriction. SynCardia also said that the C2 Driver had not been identified as the root cause of the issues, which included higher rates of mortality and cerebr...
Source: Mass Device - August 29, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Food & Drug Administration (FDA) SynCardia Source Type: news

The Implication of HeartWare HVAD Inflow Cannula Angle on Stroke and Thrombus Rate
Stroke and ventricular assist device (VAD) pump thrombus are serious complications that have previously been thought to be related to surgical placement - namely VAD inflow cannula angle. Our aim with this study was to better elucidate the impact of post-operative HeartWare HVAD (left VAD) cannula inflow angle on stroke and thrombus rate within a single centre in Sydney, Australia.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: S. Emmanuel, D. Aktuerk, A. Chowdhury, C. Hurwitz, L. Beiglari, P. Jansz, C. Hayward Tags: 1080 Source Type: research

Different Risk Factors for Ischemic and Hemorrhagic Stroke on Continuous Flow Left Ventricular Assist Device Support
Patients with end-stage heart failure on left ventricular assist devices are predisposed to stroke. Preoperative factors associated with increased stroke risk are poorly understood.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: H.K. Lamba, M. Kim, L. Hart, B. Chou, C. Rao, S. Chatterjee, S. Sattee, F. Cheema, A. Civitello, R. Delgado, A. Nair, A. Shafii, G. Loor, T. Rosengart, O. Frazier, J. Morgan Tags: 402 Source Type: research

Influence of Device Type on Stroke Risk in Women Undergoing LVAD Implantation
Stroke risk after left ventricular assist device (LVAD) implantation seems to be increased in women. The role of device type has not previously been investigated. We hypothesized that stroke risk in female patients was influenced by LVAD device type.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: R.J. Vela, J. Pruszynski, A. Amin, M. Drazner, L.C. Huffman, M. Peltz Tags: 398 Source Type: research

Impact of Stroke Onset Severity on 2-Year Survival in Destination Therapy Patients Supported by Centrifugal Flow versus Axial Flow Ventricular Assist Devices
The ENDURANCE Supplemental Trial (DT2) was designed to prospectively study whether improved blood pressure management would reduce the incidence of strokes in destination therapy patients receiving an HVAD. The trial not only demonstrated a significant reduction in hemorrhagic strokes, but also some reductions in stroke-related severity. This analysis seeks to study further the impact of stroke severity on 2-year survival in both the HVAD and control cohorts of DT2.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: P. Shah, C. Mahr, J. Rogers, M. Kiernan, S. Boyce, N.A. Mokadam, F. Pagani, T. Vassiliades, J. Teuteberg Tags: 145 Source Type: research

Understanding Risk Factors for Stroke Subtypes in the ENDURANCE Trials
Stroke is one of the most devastating morbidities associated with left ventricular assist device (LVAD) support. Improved blood pressure management in LVAD patients has been shown to significantly reduce strokes, in particular hemorrhagic strokes. However, little is known regarding clinical risk factors for stroke subtypes.
Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: S. Cho, R. Starling, J. Teuteberg, J. Rogers, F. Pagani, P. Shah, K. Uchino, T. Vassiliades Tags: 142 Source Type: research

ACC 2019: Abbott touts reduced stroke, bleeding and pump-clotting in HeartMate 3 trial
Abbott (NYSE:ABT) yesterday presented data from a new trial of its HeartMate 3 left ventricular assist device, touting a reduced rate of strokes, pump-related blood clots and bleeding episodes at two years as compared with the previous generation HeartMate II. Data in the trial was presented at the American College of Cardiology’s 68th Annual Scientific Session 2019 in New Orleans and published simultaneously in the New England Journal of Medicine, the Chicago-area medical device company said. Abbott touted its HeartMate 3 as the first implantable mechanical pump using fully magnetic levitation technology, making it fri...
Source: Mass Device - March 18, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Featured Abbott Source Type: news

Understanding Risk Factors and Predictors for Stroke Subtypes in the ENDURANCE Trials
We report a comprehensive analysis of stroke subtypes in the ENDURANCE (DT) and ENDURANCE Supplemental (DT2) trials.
Source: The Journal of Heart and Lung Transplantation - January 27, 2020 Category: Transplant Surgery Authors: Sung-Min Cho, Randall C. Starling, Jeffrey Teuteberg, Joseph Rogers, Francis Pagani, Palak Shah, Ken Uchino, Nicholas Hiivala Tags: Original Clinical Science Source Type: research

Elevated Outpatient C-Reactive Protein Independently Predicts Stroke and Gastrointestinal Bleeding in LVAD Patients
Inflammation and congestion may contribute to stroke and gastrointestinal bleeding (GIB) in LVAD pts. C-Reactive Protein (CRP), erythrocyte sedimentation rate (ESR), and N-terminal-pro B-type natriuretic peptide (NT-proBNP) are established biomarkers of inflammation and congestion. We aimed to investigate the association of these biomarkers with stroke and GIB in LVAD pts who survived to their first outpt visit.
Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: Y. Brailovsky, A. Javaid, G.M. Mondellini, L. Braghieri, M. Tiburcio, N. Uriel, G.T. Sayer, V.K. Topkara, K. Takeda, Y. Naka, R.T. Demmer, M. Yuzefpolskaya, P.C. Colombo Tags: (996) Source Type: research

Acute Anticoagulation after Ischemic Stroke in Patients with Left Ventricular Assist Devices
Despite reductions in major adverse events with the latest generation of left ventricular assist devices (LVADs), the incidence of stroke remains high. The timing of anticoagulation resumption is controversial. We aim to explore practices of anticoagulation management following ischemic stroke in LVAD patients and identify optimal strategies.
Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: C. Ibeh, D.L. Tirschwell, C. Mahr, C.J. Creutzfeldt Tags: (995) Source Type: research

Lack of Nocturnal Blood Pressure Reduction Increases the Risk of Stroke in Patients on Left Ventricular Assist Device Support
Lack of nocturnal blood pressure (BP) reduction (BP dipping) has been associated with cerebrovascular and cardiovascular events in the general population. However, the effect of a deranged circadian BP variability between day and night has never been studied in patients on left ventricular assist device (LVAD) support, where stroke still represents a major complication.We hypothesized that decreased BP dipping significantly increases the risk of stroke in patients on LVAD support.
Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: F. Castagna, G.M. Mondellini, A. Pinsino, B.J. McDonnell, E.J. St öhr, A. Gaudig, A. Amlani, J. Nwokocha, R. Te-Frey, K. Takeda, H. Takayama, Y. Naka, J.Z. Willey, M. Yuzefpolskaya, G. Parati, J. Cockcroft, P.C. Colombo Tags: (993) Source Type: research